Joshua Brody

Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T Cells with In Situ Vaccination

National Cancer Institute · R37

Contact PI · $2.6M · Icahn School of Medicine at Mount Sinai

Immunotransplant to Mantle Cell Lymphoma: Immune Response and Clinical Outcomes

National Cancer Institute · R00

Contact PI · $739.5K · Icahn School of Medicine at Mount Sinai

Immunotransplant to Treat Lymphoma: Pre-Clinical Model to Clinical Trial Design

National Cancer Institute · K99

Contact PI · $346.9K · Stanford University

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

Principal investigator · Not yet recruiting · Phase 2

Joshua Brody

Vaccination With Flt3L, Radiation, and Poly-ICLC

Principal investigator · Completed · Phase 1, Phase 2

Icahn School of Medicine at Mount Sinai

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Principal investigator · Completed · Phase 1

Icahn School of Medicine at Mount Sinai

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Principal investigator · Active not recruiting · Phase 1, Phase 2

Joshua Brody